AU2016303610A1 - Combination therapy using acamprosate and D-cycloserine - Google Patents

Combination therapy using acamprosate and D-cycloserine Download PDF

Info

Publication number
AU2016303610A1
AU2016303610A1 AU2016303610A AU2016303610A AU2016303610A1 AU 2016303610 A1 AU2016303610 A1 AU 2016303610A1 AU 2016303610 A AU2016303610 A AU 2016303610A AU 2016303610 A AU2016303610 A AU 2016303610A AU 2016303610 A1 AU2016303610 A1 AU 2016303610A1
Authority
AU
Australia
Prior art keywords
cycloserine
administered
therapeutic agent
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016303610A
Other languages
English (en)
Inventor
Craig A. Erickson
Steven L. Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Confluence Pharmaceuticals LLC
Original Assignee
Confluence Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Confluence Pharmaceuticals LLC filed Critical Confluence Pharmaceuticals LLC
Publication of AU2016303610A1 publication Critical patent/AU2016303610A1/en
Priority to AU2022202218A priority Critical patent/AU2022202218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2016303610A 2015-08-04 2016-08-04 Combination therapy using acamprosate and D-cycloserine Abandoned AU2016303610A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202218A AU2022202218A1 (en) 2015-08-04 2022-04-01 Combination Therapy Using Acamprosate And D-Cycloserine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200864P 2015-08-04 2015-08-04
US62/200,864 2015-08-04
PCT/US2016/045547 WO2017024129A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and d-cycloserine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202218A Division AU2022202218A1 (en) 2015-08-04 2022-04-01 Combination Therapy Using Acamprosate And D-Cycloserine

Publications (1)

Publication Number Publication Date
AU2016303610A1 true AU2016303610A1 (en) 2018-02-01

Family

ID=57944041

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016303610A Abandoned AU2016303610A1 (en) 2015-08-04 2016-08-04 Combination therapy using acamprosate and D-cycloserine
AU2022202218A Abandoned AU2022202218A1 (en) 2015-08-04 2022-04-01 Combination Therapy Using Acamprosate And D-Cycloserine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202218A Abandoned AU2022202218A1 (en) 2015-08-04 2022-04-01 Combination Therapy Using Acamprosate And D-Cycloserine

Country Status (11)

Country Link
US (2) US20180221315A1 (enExample)
EP (1) EP3331518A4 (enExample)
JP (2) JP2018526345A (enExample)
KR (1) KR20180034442A (enExample)
AU (2) AU2016303610A1 (enExample)
CA (1) CA2993614A1 (enExample)
HK (1) HK1255584A1 (enExample)
IL (1) IL257035A (enExample)
SG (1) SG10201914045QA (enExample)
WO (1) WO2017024129A1 (enExample)
ZA (1) ZA201800558B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016303610A1 (en) * 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURIN AND SALT THEREOF
KR102608479B1 (ko) 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
JP2025069475A (ja) * 2022-03-08 2025-05-01 ソシウム株式会社 Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤
EP4702978A1 (en) * 2023-04-27 2026-03-04 Socium Inc. Agent for treating or preventing amyotrophic lateral sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2009004082A2 (en) * 2007-07-05 2009-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticonvulsive pharmaceutical compositions
ES2530047T3 (es) * 2009-02-12 2015-02-26 Indiana University Research And Technology Corporation Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
US20100216805A1 (en) * 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013002584A2 (ko) * 2011-06-28 2013-01-03 주식회사 비보존 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도
KR102790656B1 (ko) * 2015-05-04 2025-04-02 컨플루언스 파마슈티컬스, 엘엘씨 아캄프로세이트의 스프링클 제형
AU2016303610A1 (en) * 2015-08-04 2018-02-01 Confluence Pharmaceuticals, Llc Combination therapy using acamprosate and D-cycloserine

Also Published As

Publication number Publication date
US20200360316A1 (en) 2020-11-19
AU2022202218A1 (en) 2022-04-21
KR20180034442A (ko) 2018-04-04
JP2021152060A (ja) 2021-09-30
US20180221315A1 (en) 2018-08-09
JP2018526345A (ja) 2018-09-13
WO2017024129A1 (en) 2017-02-09
SG10201914045QA (en) 2020-03-30
IL257035A (en) 2018-03-29
CA2993614A1 (en) 2017-02-09
EP3331518A1 (en) 2018-06-13
EP3331518A4 (en) 2019-04-03
ZA201800558B (en) 2019-10-30
HK1255584A1 (zh) 2019-08-23

Similar Documents

Publication Publication Date Title
AU2022202218A1 (en) Combination Therapy Using Acamprosate And D-Cycloserine
JP2023171776A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
JP6957455B2 (ja) ベータ細胞の複製及び／または生存の亢進
JP6951976B2 (ja) 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現
JP2017510607A5 (enExample)
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
US20090264522A1 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
JP2023134691A (ja) フペルジンの放出調節医薬組成物およびその使用方法
CN115605195A (zh) 用于治疗大麻使用病症和缓解大麻素戒断的方法和组合物
WO2008047365A1 (en) Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
CA2735834C (en) Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis
ES3031676T3 (en) Use of higher doses of modified release huperzine formulations
JP2021530568A5 (enExample)
JP2014530249A5 (enExample)
CN103635194B (zh) 用于治疗早泄的药物组合物以及用于治疗早泄的方法
CN115835862A (zh) 治疗阿尔茨海默病的组合及其应用
WO2022037006A1 (zh) 一种止痛止痒药物组合物及其应用方法
RU2590978C1 (ru) Капсулированный препарат для лечения простуды и способ его получения
JP7656339B2 (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
US20170354667A1 (en) Composition and method for treating bipolar disorder
TW202448432A (zh) 肌萎縮性側索硬化症（ａｌｓ）的治療
Mentazac Almuriva (UK); Altigmin (Turkey); Alzerta (Spain); Alzest (UK); Alzigmine (Israel).• Balaxon (Greece); Begusin (Poland).
CN101816673A (zh) 包含左旋多巴和胞二磷胆碱药物制剂及在帕金森病中用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted